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Purpose: The aims were to analyze the temporal evolution of neutrophil apoptosis, to determine the
differences in neutrophil apoptosis among 28-day survivors and nonsurvivors, and to evaluate the use of
neutrophil apoptosis as a predictor of mortality in patients with septic shock.
Materials and Methods: Prospective multicenter observational study carried out between July 2006 and
June 2009. The staining solution study included 80 patients with septic shock and 25 healthy volunteers.
Neutrophil apoptosis was assessed by fluorescein isothiocyanate (FITC)–conjugated annexin V and
aminoactinomycin D staining.
Results: The percentage of neutrophil apoptosis was significantly decreased at 24 hours, 5 days, and 12
days after the diagnosis of septic shock (14.8% ± 13.4%, 13.4% ± 8.4%, and 15.4% ± 12.8%, respectively;
P b .0001) compared with the control group (37.6% ± 12.8%). The difference in apoptosis between 28-day
surviving and nonsurviving patients was nonsignificant (P N .05). Themortality rate at 28 days was 53.7%.☆ Conflict of Interest: None declared.
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415.e2 E. Tamayo et al.The crude hazard ratio for mortality in patients with septic shock did not differ according to the percentage
of apoptosis (hazard ratio, 1.006; 95% confidence interval, 0.98-1.03; P = .60).
Conclusions: During the first 12 days of septic shock development, the level of neutrophil apoptosis
decreases and does not recover normal values. No differences were observed between surviving and
nonsurviving patients.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Sepsis affects more than 500 000 patients annually in the
United States [1], with an estimated incidence in Europe of 240
to 400 cases per 100 000 inhabitants per year [2], and the
incidence rate continues to increase [1,2]. Of the patients
admitted to intensive care units (ICUs), the incidence of severe
sepsis or septic shock is between 9% and 37% [1-4]. In spite of
recent advances in treatment with antibiotics and critical care
therapy, sepsis still results in a highmortality rate; it is typically
between 40% and 60% in the case of septic shock [1-5]. Septic
shock and multiple organ dysfunction syndrome (MODS) are
the most common causes of death in ICUs [4].
The lack of apoptosis regulation in patients with severe
injuries contributes to the pathogenesis of MODS [6]. The
systemic inflammatory response can harm the patient through
either an inadequate or excessive inflammatory reaction [7].
Apoptosis is vital to the regulation of neutrophils, monocyte
eosinophils, and macrophages. With sepsis, a delay in
neutrophil apoptosis [8] and increased apoptosis in hemato-
poietic tissues, such as the thymus, Peyer patch, spleen, and
bone marrow, is frequently observed [9]. The prolonged
neutrophil survival may allow a more robust inflammatory
response and, thus, better protect the individual. However,
neutrophil survival may also cause harm to the host, leading
to the development of MODS and increasing mortality by
increasing the number of leukocytes or the production of
proinflammatory mediators and free radicals [10-12].
Although the significant reduction in neutrophil apoptosis
has been sufficiently established in patients with sepsis
[8,10], the temporal course of this phenomenon during the
clinical evolution of septic shock has not been studied in
either surviving or nonsurviving patients. The use of
neutrophil apoptosis as a predictor of survival in patients
with septic shock has also not been studied.
Based on the fact that the reduction in neutrophil
apoptosis during septic shock is related to the development
of MODS [6,10,11], we hypothesize that the levels of
neutrophil apoptosis in patients who survive septic shock
will continue to increase throughout its evolution until
normal levels, values equivalent to those found in healthy
controls, are reached, and these levels will be different (ie,
higher) than those in nonsurviving patients.
The aim of this study was to analyze the following in
patients with septic shock: (1) temporal changes in
neutrophil apoptosis, (2) differences in neutrophil apoptosis
between 28-day survivors and 28-day nonsurvivors, (3) theuse of neutrophil apoptosis as a predictor of mortality, and
(4) evaluation of the factors that may influence the course of
the apoptosis.2. Materials and methods
2.1. Study design, patients, and healthy volunteers
From July 2006 through June 2009, eligible patients were
enrolled in this open-label, prospective, nonrandomized,
multicenter, nondrug interventional study, which was con-
ducted at 4 medical/surgical ICUs in Valladolid, Spain:
postoperative general, postoperative cardiac surgery, and
medical ICUs of the Hospital Clinico Universitario and the
postoperative general ICU of the Hospital Universitario Río
Hortega. The study protocol was reviewed and approved by
the Human Subjects Review Committee and Research Ethics
Board of the Hospital Clínico Universitario of Valladolid, and
informed consent was obtained from each study participant.
The study only included patients older than 18 years who
were in septic shock with at least 2 dysfunctional organs or
systems at the time of enrollment, as previously described by
Bone et al [7] (Appendix A). The patients were enrolled in
the first 24 hours after the diagnosis of septic shock. Patients
were excluded if they had a known metastatic malignant
disease or HIV, were receiving immunosuppressive drugs or
systemic corticosteroids, or were enrolled in a concomitant
interventional study.
Over the course of the study, a total of 92 patients met the
criteria for inclusion; however, 12 patients had incomplete
follow-up and were withdrawn from the study. In total, the
study included 80 patients and 25 healthy volunteers, who
were included as normal controls (Appendix B). The 80
septic shock patients had a mean age (±SD) of 68.7 ± 12.4
years and consisted of 52 men (65.0%) and 28 women
(35.0%). The mean age (±SD) of the 25 healthy controls was
68.5 ± 17.3 years and consisted of 15 men (60.0%) and 10
women (40.0%). No significant differences were observed
between the 2 groups with respect to age or sex (P N .05).
The septic shock patients included in the study were
divided into 2 groups: 28-day nonsurvivors and 28-day
survivors (Appendix B). A follow-up period of 12 days was
established for the evolution of apoptosis based on data from
previous studies concerning the duration of stay in the
hospital and ICU. Rivers et al [13] reported a mean hospital
415.e3Apoptosis in septic shockstay of 13.0 ± 13.7 days; Angus et al [1] reported a mean ICU
stay of 15.7 ± 7 days; Esteban et al [2] reported a mean ICU
stay of 9 days (range, 4-25 days); and Ferreira et al [14]
reported a mean ICU stay of 4.0 days (range, 1-56 days).
Patients were treated according to the best standard of care
for severe sepsis. The therapeutic measures were those
habitually used in the ICUs in which the studywas conducted.
2.2. Blood samples, neutrophil isolation, and
neutrophil apoptosis
2.2.1. Blood samples
A blood sample of 10 mL was obtained from each patient
immediately after providing informed consent (24 hours), at
5 days, and at 12 days. A single peripheral blood extraction
of 10 mL was obtained from each healthy control. The blood
samples were placed in tubes containing citrate and glucose,
and the samples were sent to the laboratory of the Valladolid
Institute of Biology and Molecular Genetics for analysis.
2.2.2. Isolation of neutrophils
Neutrophils were isolated as described previously [14].
Fresh bloodwasmixed 6:1 (vol/vol) with acid-citrate-dextrose.
Dextran (T500 Pharmacy) (Pharmacosmos A/S, Holbaek,
Denmark) was added to a final concentration of 1.3%. After 45
minutes at room temperature, the upper layer containing no red
blood cells was centrifuged (300g, 10 minutes). The cell pellet
was resuspended and layered on a Ficoll gradient (Lymphocyte
Separation Medium; Flow Laboratories, Irvine, UK). After 40
minutes of centrifugation (400g), the pellet containing
neutrophils was recovered and contaminating red cells
disrupted by hypotonic lysis. Neutrophils were resuspended
in 1-mL phosphate-buffered saline and counted by trypan blue
exclusion. Viability was more than 95%. To confirm cell
viability, we measured cytosolic calcium in parallel experi-
ments. Cells were able to respond with calcium increases in
response to fMet-Leu-Phe: formal-methionyl-leucyl-phenylal-
anine and platelet-activating factor.
2.3. Neutrophil apoptosis
Neutrophil apoptosis was detected using a technique
combining fluorescein isothiocyanate (FITC)–conjugated
annexin V (annexin V-FITC) and 7-aminoactinomycin D (7-
ADD) (Molecular probes; Invitrogen; Paisley, Renfrewshire,
UK) staining solution (Annexin V-FITC Apoptosis Detection
kit I; BDPharMingen, SanDiego,CA). The polymorphonuclear
suspension (100 μL) in cold binding buffer (200 000 cells/mL)
was transferred to 4 culture tubes to which 5 μL of annexin V
(BD PharMingen) was added. After incubation in the dark at
room temperature for 15minutes, 400μL of annexinV–binding
buffer (BD PharMingen) and 0.4 μL of a 1 mg/mL stock of 7-
ADD were added to each tube for flow cytometry (FACSCa-
libur; Becton Dickinson, Fullerton, CA). Gating based on
forward and side-scatter detection was applied to eliminate cell
debris. A minimum of 10 000 events were acquired per sample.Gated events were plotted for annexin V-FITC and 7-ADD
staining. Results were reported as the percentage of viable cells,
cells in the early stages of apoptosis (annexin V-FITC positive
and 7-ADDnegative), or dead cells (Fig. 1). All the experiments
were made in by duplicate with controls with only 7-ADD and
only annexin V to perform compensation.
We carried out a morphological control of apoptosis in
parallel experiments: neutrophils were stained with May-
Grünwald-Giemsa; the cells that showed shrinkage, nuclear
coalescence, and nuclear chromatin condensation were
considered as apoptotic; the number was very similar to
annexin V results: apoptosis values were very different
ranging from 13.8% ± 2.1% in septic patients to 46.7 ± 3.7 in
control neutrophils (Fig. 1B) [15].
2.4. Study variables
2.4.1. Outcome variables
The primary outcome variable was the mean percentage
of neutrophil apoptosis.
2.4.2. Independent variables
Independent variables included age, sex, prior or
preexisting conditions (hypertension, coronary artery dis-
ease, other heart disease, congestive heart failure, diabetes
mellitus, chronic pulmonary disease, liver disease, cancer,
chronic renal failure), admission category (medical, elective
surgery, emergency surgery, type surgery), severity of septic
shock (Acute Physiology and Chronic Health Evaluation
[APACHE] II score [16]; Sequential Organ Failure Assess-
ment [SOFA] score [17]; acute respiratory distress syn-
drome; lactate; C-reactive protein [CRP]; central venous
oxygen saturation [ScvO2]; procalcitonin; vasopressor use;
time to extubation; leukocyte count measured at 24 hours, 5
days, and 12 days; length of hospital stay; and length of ICU
stay, 28-day mortality, and in-hospital mortality from the
time of sepsis diagnosis), specific strategies for the
pharmacologic treatment of sepsis (insulin therapy directed
at maintaining a blood glucose level b150 mg/dL blood, low-
dose steroid therapy, activated protein C therapy, appropriate
antibiotic therapy), site of infection, and culture results on the
day of the study. Appropriate empiric antibiotic treatment
was defined when at least one of the drugs administered was
effective against the pathogens obtained on the antibiogram
and administered immediately after the microbiological
diagnostic test and continued for at least 5 days or until
death. The only exception was the case of Pseudomonas
aeruginosa, in which 2 effective drugs were required.
2.5. Determination of sample size
The sample size calculation was based on the percentage
of neutrophil apoptosis in healthy volunteers, as opposed to
that of patients with septic shock, from published studies. At
the start of the study (at 24 hours), the frequency of
neutrophil apoptosis in patients with septic shock was
Fig. 1 Representative results of neutrophil apoptosis assessed by 7-ADD and annexin V-FITC staining in a patient with sepsis and a healthy
volunteer. Photograph representing neutrophil apoptosis with May-Grünwald-Giemsa staining. Right side of figure: cells that stained positive
for annexin V-FITC and negative for 7-ADD were in the early stages of apoptosis (lower right quadrant; 45.1% patient with sepsis [A]; 15.5%
control [B]). Cells staining positive for both annexin V-FITC and 7-ADD were either in the later stages of apoptosis or necrotic (upper right
quadrant). Cells negative for both were viable and not undergoing apoptosis (lower left quadrant). Results are expressed as a percentage in each
quadrant. Left side of figure: annexin V-FITC–positive cells, healthy volunteer (A). B, Patient with sepsis. Photograph: contains media data
values of apoptosis neutrophils in septic patients (A) vs in healthy volunteer (B). May-Grünwald-Giemsa–stained cells showed shrinkage,
nuclear coalescence, and nuclear chromatin condensation.
415.e4 E. Tamayo et al.between 9% and 28%, whereas the frequency in healthy
subjects was between 50% and 70% [8,11,18,19].
The null hypothesis of this study was that the levels of
neutrophil apoptosis in patients with septic shock are not
equivalent to those in healthy controls at the end of their
clinical evolution (12 days). For this study, a less than 20%
difference in the level of neutrophil apoptosis between
healthy controls and patients with septic shock was taken as
an alternative hypothesis. Based on this assumption, for a
single-tailed test with an error probability of 5% and a power
of 80%, a sample size of 20 healthy controls and 80 patients
with septic shock was established.
2.6. Data analysis
To test the null hypothesis that the level of neutrophil
apoptosis is different in healthy controls and patients withseptic shock, the 95% confidence interval (CI) for the
difference between the mean apoptosis values (end point for
the septic shock patients and baseline-unique value for
controls) was calculated. Analyses were similarly performed
for 28-day survivors and nonsurvivors.
To explore whether baseline apoptosis values can predict
28-day mortality, a Cox regression model was applied to
the data, where the dependent variable was the time of
death and the independent variables were baseline apopto-
sis values, therapeutic interventions (activated protein C
therapy, appropriate antibiotic therapy, low-dose steroid
therapy, insulin therapy directed at maintaining a blood
glucose level b150 mg/dL blood), disease severity
measures (admission APACHE II score and admission
SOFA score), sex, and age. The multivariate analysis of 28-
day survival was based on the standard Cox continuous
proportional hazards model using a stepwise approach [20].
415.e5Apoptosis in septic shockThe explanatory variables were used in a categorized or
dichotomized form.
The relative hazard (RR = exp(βi)) was used as a measure
of the risk of death in different groups, where βi is the basic
parameter in the Cox model. Kaplan-Meier estimates of
mortality, along with risk ratios and 95% CIs were used to
describe the relative risk of death. These curves were
compared using the log-rank test.
Multiple linear regression models were used to assess the
association of the percentage of neutrophil apoptosis from the
onset of sepsis with the following variables: age, sex, indexesTable 1 Characteristics of the study population
Characteristics Nonsur
Age (y), mean ± SD 70.1 ±
Sex, M/F, n (%) 28 (53.
Prior or preexisting conditions, n (%)
Hypertension 22 (51.
Coronary artery disease 5 (11.6
Other heart disease 10 (23.
Congestive heart failure 8 (18.6
Diabetes mellitus 12 (27.
Chronic pulmonary disease 7 (16.3
Liver disease 7 (16.3
Cancer 8 (18.6
Chronic renal failure 11 (25.
Admission category, n (%)
Medical 10 (23.
Elective surgery 27 (62.
Emergency surgery 24 (55.
Type surgery
Cardiac surgery 10 (23.
Abdominal surgery or peritonitis 18 (41.
Cerebral trauma or brain surgery 1 (2.3)
Thoracic surgery 0 (0.0)
Vascular surgery 3 (6.9)
Others surgery 0 (0.0)
Severity of septic shock
APACHE II points, mean ± SD 24.9 ±
SOFA points, mean ± SD 9.8 ± 2
ARDS, mean ± SD 40 (93)
Arterial lactate (mEq/L), mean ± SD 3.7 ± 3
CRP (mg/L), mean ± SD 249.9 ±
ScvO2 (%) 76.3 (1
Procalcitonin (ng/mL), mean ± SD 28.6 ±
Use of vasopressors, n (%) 43 (100
Time to extubation (d) 15.1 ±
Leukocyte count (cells/mm3) at 24 h, mean ± SD 18 480
Leukocyte count (cells/mm3) at 5 d, mean ± SD 17 930
Leukocyte count (cells/mm3) at 12 d, mean ± SD 19 441
Length of ICU stay (d), mean ± SD 23.3 ±
Length of hospital stay (d), mean ± SD 28.2 ±
Specific strategies for pharmacologic treatment in sepsis, n (%)
Maintain blood glucose level b150 mg/dL, n (%) 28 (65.
Low-dose steroid therapy, n (%) 24 (55.
Activated protein C therapy, n (%) 13 (30.
Appropriate antibiotic therapy, n (%) 18 (41.
ARDS indicates acute respiratory distress syndrome. P ≤ .05 was considered siof severity (SOFA, APACHE II, lactate level, ScvO2),
pharmacologic treatment of sepsis (blood glucose level, low-
dose steroid therapy, activated protein C therapy, appropriate
antibiotic therapy), procalcitonin, and bacteriemia.
Data are presented as mean ± SD. Statistical analyses
were performed using the SPSS software program (version
15.0, Chicago, IL). We used the χ2 test and Fisher exact test,
to compare categorical variables, and the Student t test, to
compare continuous variables, as appropriate.
The difference from baseline and between the groups was
evaluated by 2-way analysis of variance for repeatedvivors, n = 43 Survivors, n = 37 P
11.4 66.9 ± 13.6 .26
8)/15 (35.4) 24 (53.6)/13 (46.4) 1.00
2) 19 (51.3) 1.00
) 6 (16.2) .53
2) 6 (16.2) .57
) 4 (10.8) .36
9) 9 (24.3) .80
) 13 (35.1) .06
) 5 (13.5) 1.00
) 9 (24.3) .58
6) 3 (8.1) .07
2) 10 (27.0) .47
8) 33 (89.2) .95
8) 18 (48.6) .65
3) 7 (18.9) .64
9) 15 (40.5) .90
1 (2.7) .91
1 (2.7) .28
2 (5.4) .77
3 (8.1) .06
5.1 21.1 ± 5.2 .03
.6 8.9 ± 2.9 .16
32 (86.5) .52
.5 3.1 ± 2.1 .43
123.6 269.8 ± 125.9 .50
1.0) 77.6 (10.8) .44
45.1 48.7 ± 73.4 .18
) 37 (100) 1.00
14.2 19.9 ± 14.2 .13
.7 ± 8436.2 18 606.9 ± 9472.6 .95
.3 ± 9889.9 15 536.8 ± 7482.3 .29
.9 ± 11028.9 13 822.6 ± 5877.9 .04
25.0 16. ± 5.4 .000
20.0 16.4 ± 13.6 .003
1) 13 (35.1) .02
8) 16 (43.2) .64
2) 8 (21.6) .61
9) 27 (72.9) .004
gnificant.
415.e6 E. Tamayo et al.measurements (analysis of variance followed by Scheffe
test). Correlation analysis between variables was performed
using Pearson correlation coefficient. A probability value of
P ≤ .05 was considered significant.3. Results
3.1. Patient demographics and clinical
characteristics
Table 1 shows the characteristics of the septic shock patients
and their distribution according to 28-day mortality. At
baseline, the demographics and severity of septic shock were
similar in the 28-day nonsurvivor group (n = 43) and the 28-day
survivor group (n = 37). Notably, in the nonsurviving group, the
APACHEscore (P= .03), length of ICU stay (P= .0001), length
of hospital stay (P = .003), and leukocyte count at 12 days (P =
.04) were increased compared with survivors, whereas the
number of patients undergoing appropriate antibiotic therapy
(P = .004) or receiving insulin therapy to maintain blood
glucose less than 150 mg/dL (P = .02) was less (Table 1).
The lungs and the abdomen were the most common sites
of infection, occurring in 50.0% and 26.2% of the patients in
the 2 groups, respectively (Table 2). The incidence of gram-
positive, gram-negative infections and fungus was similar in
the 2 groups (Table 2).Table 2 Sites of infection and types of microorganisms causing infe
Variable Total, n = 80 No
Site of infection, a n (%)
Lung 40 (50.0) 19
Intra-abdominal 21 (26.2) 15
Urinary tract 7 (8.7) 2
Other b 12 (15.0) 5
Positive blood culture 34 (42.5) 19
Type of organism, c n (%)
Gram-positive cocci 31 (38.7) 17
Aureus staphylococcus 9 (11.2) 5
Methicillin resistant 6 (7.5) 4
Methicillin susceptible 3 (3.7) 1
Epidermidis staphylococcus 8 (10.0) 4
Streptococcus species 5 (6.2) 3
Enterococcus species 9 (11.2) 5
Gram-negative bacilli 55 (68.7) 26
Pseudomonas aeruginosa 9 (11.2) 3
Klebsiella pneumoniae 15 (18.7) 7
Acinetobacter baumannii 4 (5.0) 3
Other gram-negative 27 (33.7) 13
Fungus 15 (18.7) 8
Candida albicans 8 (10.0) 5
Other Candida species 7 (8.7) 3
P ≤ .05 was considered significant.
a The site of infection was either documented or presumed based on clinica
b Other sites of infection included the blood, skin, central nervous system,
c Patients may have had more than 1 organism cultured.3.2. Neutrophil apoptosis
A significant decrease in neutrophil apoptosis (annexin V-
FITC positive and 7-ADD negative) was observed in septic
shock patients at 24 hours, 5 days, and 12 days after
diagnosis (14.8% ± 13.4%, 13.4% ± 8.4%, and 15.4% ±
12.8%, respectively) compared with healthy volunteers
(37.6% ± 12.8%; P b .0001; Fig. 2). No significant difference
in neutrophil apoptosis was observed between 28-day
nonsurvivors and survivors (P N .05; Fig. 3).
3.3. Correlation percentage of neutrophil apoptosis
and plasma neutrophil levels
Correlation analysis provided no evidence that the
percentage of neutrophil apoptosis at 24 hours, 5 days, and
12 days from the start of septic shock is related to the plasma
neutrophil level in surviving patients (24 hours, r = 0.09, P =
.592; 5 days, r = 0.37, P = .88; 12 days, r = 0.48, P = .12) or
nonsurviving patients (24 hours, r = 0.08, P = .58; 5 days,
r = 0.40, P = .01; 12 days, r = 0.08, P = .70).
3.4. 28-day mortality and apoptosis
The mortality rate at 28 days was 53.7% (43/80) with
an in-hospital mortality of 68.7% (55/80). The crude
hazard ratio (HR) of mortality for patients with septicction in patients with septic shock
nsurvivors, n = 43 Survivors, n = 37 P
(44.2) 21 (56.7) .21
(34.8) 6 (16.2) .20
(4.6) 5 (13.5) .16
(11.6) 7 (18.9) .36
(44.2) 15 (40.5) .74
(39.5) 14 (37.8) .30
(11.6) 4 (10.8) .91
(9.3) 2 (5.4) .51
(2.3) 2 (5.4) .47
(9.3) 4 (10.8) .82
(7.0) 2 (5.4) .77
(11.6) 4 (10.8) .91
(60.5) 29 (78.4) .08
(6.9) 6 (16.2) .11
(16.3) 8 (21.6) .50
(6.9) 1 (2.7) .39
(30.2) 14 (37.8) .41
(18.6) 7 (18.9) .92
(11.6) 3 (8.1) .60
(6.9) 4 (10.8) .55
l findings.
bones and joints, cardiac system, and reproductive organs.
Fig. 2 Comparison of the mean percentage of neutrophil apoptosis between healthy controls (dark bars) and patients in septic shock (light
bars) at different sampling times after the start of septic shock. Significant differences were observed between the control group and septic
patients at the 3 time points studied.
415.e7Apoptosis in septic shockshock who survived to day 28 did not differ from
nonsurvivors according to the mean percentage of
apoptosis at baseline (at 24 hours, HR, 1.006; 95% CI,
0.98-1.03; P = .60).Fig. 3 Comparison of the mean percentage of neutrophil apoptosis be
patients (dark bars) at different sampling times after the start of septic shoc
the 3 time points studied.After performing the Cox multivariant analysis adjust-
ment for factors (Table 3), the mean percentage of apoptosis
measured at 24 hours did not stand out as an independent
mortality risk factor (HR, 1.004; 95% CI, 0.96-1.04;tween 28-day nonsurviving (light bars) and surviving septic shock
k. No significant differences were observed between the 2 groups at
Table 3 Independent variables selected by the stepwise Cox
regression analysis model as associated with 28-day ICU
mortality
Characteristics P Adjusted HR
(95.0% CI)
Sex (female, 1) .95 0.98 (0.45-2.11)
Age (y) .47 1.01 (0.97-1.05)
APACHE II .04 1.13 (1.003-1.28)
SOFA .63 0.95 (0.78-1.15)
Blood glucose level b150 mg/dL .51 0.99 (0.98-1.008)
Low-dose steroid therapy .38 1.40 (0.65-3.03)
Activated protein C therapy .30 1.48 (0.70-3.11)
Appropriate antibiotic therapy .001 3.46 (1.64-7.26)
Apoptosis .83 1.004 (0.96-1.04)
P ≤ .05 was considered significant.
415.e8 E. Tamayo et al.P = .83). The only identifiable independent mortality risk
factors were appropriate antibiotic therapy and the APACHE
II score. Thus, the mortality rate at 28 days was 3.46 times
greater (95% CI, 1.64-7.26; P = .001) in patients who
received an incorrect antibiotic treatment compared with
patients who received the correct treatment. The mortality
rate was also greater with a greater APACHE II score
(adjusted HR, 1.13; 95% CI, 1.002-1.28; P = .04).
3.5. Determinant apoptosis factors
Analyzing, by means of multiple linear regression, the
effect of the different factors on the percentage of
neutrophil apoptosis, from day 1 of the onset of sepsis,
revealed that age was inversely associated with apoptosis
(β = .40; t = 2.34; P = .02; 95% CI, 0.06-0.93),
whereas blood glucose level (β = .44; t = 2.52; P = .01;
95% CI, 0.01-0.12) and lactate level (β = .48; t = 2.36;
P = .02; 95% CI, 0.05-0.79) were positively associated
with it (Table 4).Table 4 Multiple linear regression analyses showing the relationship
Variable SE β
Constant 35.41
Age (y) 0.21 0.40
Sex 4.22 0.22
SOFA 1.04 0.12
APACHE II 0.57 0.17
Lactate level 0.17 0.48
ScvO2 0.20 0.14
Procalcitonin 0.09 0.31
Blood glucose level 0.02 0.44
Low-dose steroid therapy 4.47 0.09
Activated protein C therapy 4.57 0.07
Appropriate antibiotic therapy 4.49 0.18
Bacteriemia 4.56 0.13
β indicates standardized regression coefficient; t, corresponding t values. P ≤ .04. Discussion
The 2 most relevant findings of this study are that
neutrophil apoptosis is decreased in patients with septic
shock for at least 12 days with no significant differences
between 28-day nonsurvivors and survivors and that
neutrophil apoptosis is not an independent predictor of
mortality risk. In addition, it was observed that apoptosis was
greater in relationship with higher levels of blood glucose
level and lactate level and lower as age increased.
The term apoptosis (from the Greek “fall of the leaves”)
was introduced by Kerr et al [21] in 1971 to describe a
physiologic cell death distinct from necrosis or pathologic
cell death. In recent years, the study of apoptosis in sepsis has
gained interest due to the fact that it can help explain part of
the enigmatic pathophysiology of this illness. Most studies
carried out along these lines come from preclinical research,
using experimental models of sepsis, that are often based on
lethal bacterial toxin-based studies, monospecific intrave-
nous microbial challenge, or pretreatment approaches, which
do not replicate septic patients' status adequately in clinical
practice [10].
Delayed neutrophil apoptosis has been documented in
animals and septic patients only during the first 24 hours
after the diagnosis of sepsis [18,22,23]. Guo et al [23]
demonstrated that neutrophils in septic mice survive longer
compared with nonseptic mice [23]. In septic patients, the
decrease in neutrophil apoptosis was also documented by
Taneja et al [18], reporting the percent neutrophil apoptosis
in healthy controls as 52% ± 7.8% compared with 6.2% ±
1.1% in septic patients; Martins et al [19], reporting the
median neutrophil apoptosis in healthy controls as 11.3% vs
9.1% in septic patients; Härter et al [8], reporting a median
percent neutrophil apoptosis of 64% in healthy controls vs
28.8% in septic patients; and Fialkow et al [11], who
reported a median percent neutrophil apoptosis in healthy
controls of 69% ± 1.1% vs 38% ± 3.7% in septic patients. Tobetween variables and apoptosis
t P 95% CI
−2.97 .006 (−178.17, −32.60)
2.34 .02 (0.06, 0.93)
1.51 .14 (−2.26, 15.10)
0.75 .45 (−1.35, 2.93)
0.86 .39 (−0.68, 1.68)
2.36 .02 (0.05, 0.79)
0.83 .41 (−0.25, 0.60)
1.67 .10 (−0.03, 0.35)
2.52 .01 (0.01, 0.12)
0.58 .56 (−6.57, 11.84)
0.47 .64 (−7.24, 11.55)
1.14 .26 (−4.08, 14.37)
0.80 .43 (−5.72, 13.03)
5 was considered significant.
415.e9Apoptosis in septic shockthe contrary of that previously stated, our results confirm
decreased neutrophil apoptosis not only during the first 24
hours after the onset of sepsis but also that this reduction is
maintained over a period of at least 12 days.
In the present study, we detected no differences in
neutrophil apoptosis between nonsurviving and surviving
patients. This finding may be due to the fact that septic shock
is the most serious form of sepsis and produces a more
intense inhibition of apoptosis [11]. Consequently, the return
to normal values of apoptosis in surviving patients happens
later. Similarly, the present study found no correlation
between decreased plasma neutrophil apoptosis and leuko-
cytosis in surviving and nonsurviving patients. This fact is
surprising because an important mechanism of leukocytosis
that can be observed in septic shock is explained by the
stimulation of leukocyte production in the bone marrow [24].
On the other hand, we did observe lower blood leukocyte
levels in surviving patients on day 12 of septic shock.
The 28-day mortality observed in the present study was
similar to that reported in other studies including patients
with the same clinical risk [25]. The patients included in our
study had an average APACHE score of 23.2 and SOFA
score of 9.4, and Cox multiple regression analysis did not
show that the mean percentage of apoptosis is an
independent predictor of mortality in patients with septic
shock. We must point out that, of the independent variables
selected by Cox regression analysis, we only identified
correct antibiotic treatment as an independent risk factor for
mortality. This result strengthens the recommendations of
the Surviving Sepsis Campaign [26], which showed that
correct, early, wide-spectrum antibiotherapy is a fundamen-
tal pillar in handling sepsis.
Different factors have been cited as being able to
influence neutrophil apoptosis (age, blood glucose level,
corticoids, hypoxia, tobacco, etc) [27,28]; however, they
have not been analyzed in patients with sepsis. In our study,
carried out on patients with sepsis, we observed greater
neutrophil apoptosis in those with higher levels of blood
glucose level and lactate level and lesser as age increased.
These findings are concordant with those observed inmedical literature and described under different conditions
[27,28]. We believe that, as this study was not designed to
clarify these issues, other studies should be carried out aimed
at analyzing them in more detail.
The present study has 2 main limitations. First, the
evaluation of neutrophil apoptosis was carried out during the
first 12 days after the onset of the clinical symptoms of septic
shock. However, the study lasting until the normalization of
apoptosis would possibly have been of interest. Furthermore,
because apoptosis occurs via a complex signaling cascade
that is tightly regulated at multiple points, there are many
opportunities to evaluate the activity of the proteins involved
(cytomorphological alterations, DNA fragmentation, detec-
tion of caspases, membrane alterations, detection of
apoptosis in whole mounts, mitochondrial assays) [29].
There are a large variety of assays available, but each assay
has advantages and disadvantages [29]. We have used
annexin V-FITC labeling to measure apoptosis. The
advantage is sensitivity (it can detect a single apoptotic
cell). The disadvantage is that the membranes of necrotic
cells are labeled as well. To avoid that and to demonstrate the
membrane integrity of the phosphatidylserine-positive cells,
neutrophils were stained simultaneously with 7-ADD and in
parallel with May-Grünwald-Giemsa. The cells that showed
shrinkage, nuclear coalescence, and nuclear chromatin
condensation were considered as apoptotic.5. Conclusions
In conclusion, over the first 12 days of septic shock
development, the level of neutrophil apoptosis decreased and
did not return to normal values, with no difference between
surviving and nonsurviving patients. Moreover, the deter-
minant factors for apoptosis levels were age, blood glucose
level, and lactate level. Consequently, we concluded that
apoptosis in sepsis is a phenomenon that requires further
study to clearly determine its role before proposing that new
medical treatments for sepsis have antiapoptotic effects.
415.e10 E. Tamayo et al.Appendix A. Summary of inclusion criteriaInfection criteria Modified SIRS criteria For dysfunctional organs or systems ⁎Patients had to have a known infection or a
suspected infection, as evidenced by one
or more of the following: white cells in a
normally sterile body fluid; perforated
viscus; radiographic evidence of
pneumonia in association with the
production of purulent sputum; a
syndrome associated with a high risk of
infection (eg, ascending cholangitis)Patients had to meet at least 3 of the following
4 criteria: a core temperature of ≥38°C
(100.4°F) or ≤36°C (96.8°F); a heart rate of
≥90 beats per min, except in patients with a
medical condition known to increase the heart
rate or those receiving treatment that would
prevent tachycardia; a respiratory rate of ≥20
breaths per min or a Paco2 of ≤32 mm Hg or
the use of mechanical ventilation for an acute
respiratory process; a white cell count of
≥12 000/mm3 or ≤4000/mm3 or a
differential count showing N10% immature
neutrophilsPatients had to meet at least 1 of the
following 5 criteria: for cardiovascular
system dysfunction, the arterial systolic
blood pressure had to be ≤90 mm Hg or the
mean arterial pressure ≤70 mm Hg for at
least 1 hour despite adequate fluid
resuscitation, adequate intravascular volume
status, or the use of vasopressors in an
attempt to maintain a systolic blood pressure
of ≥90 mm Hg or a mean arterial pressure
of ≥70 mm Hg; for kidney dysfunction,
urine output had to be b0.5 mL/kg of body
weight per hour for 1 hour, despite adequate
fluid resuscitation; for respiratory system
dysfunction, the ratio of Pao2 to FiO2 had to
be ≤250 in the presence of other
dysfunctional organs or systems or ≤200 if
the lung was the only dysfunctional organ;
for hematologic dysfunction, the platelet
count had to be b80 000/mm3 or to have
decreased by 50% in the 3 days preceding
enrollment; in the case of unexplained
metabolic acidosis, the pH had to be ≤7.30
or the base deficit had to be≥5.0 mmol/L in
association with a plasma lactate level that
was N1.5 times the upper limit of the normal
value for the reporting laboratorySIRS denotes systemic inflammatory response syndrome; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; and
FiO2, fraction of inspired oxygen.
⁎ The first sepsis-induced organ or system dysfunction had to develop within 24 hours before study enrollment.Appendix B. Patients and healthy volunteersAppendix C. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.jcrc.2011.09.001.References
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